Publications

5674 Results

Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Metastatic Basal Cell Carcinoma

Authors
S Patel;E Cano-Linson;Y Chae;S Schokrpur;C Lao;B Powers;A Victor;A Onitilo;S Shin;N Takebe;S Threlkel;C McLeod;H Chen;E Sharon;M Othus;C Ryan;C Blanke;R Kurzrock
Journal / Conference
NPJ Precision Oncology
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID39856213
PMC
PMC11759674
Study Number(s)
S1609

Urine tumor DNA detection predicts response to atezolizumab in BCG-unresponsive non-muscle-invasive bladder cancer

Authors
M St-Laurent;P Singh;D McConkey;MS Lucia;V Koshkin;K Stratton;T Bivalacqua;W Kassouf;S Porten;R Bangs;M Plets;I Thompson;J Meeks;V Caruso;C Ward;B Mazzarella;K Philllips;V Bicocca;T Levin;S Lerner;P Black
Journal / Conference
European Urology
Year
2025
Research Committee(s)
Genitourinary
PMID
PMID40404526
Study Number(s)
S1605

Best practices and pragmatic approaches for PRO/QOL measures in cancer clinical trials

Authors
H Bandos;P Torres-Saavedra;E Culacova;H Gunn;M Lee;F Duan;R Cecchini;J Unger;A Dueck;J Steingrimsson
Journal / Conference
Journal of the National Cancer Institute Monographs Mar 1;2025(68):14-21
Year
2025
Research Committee(s)
Cancer Care Delivery and Melanoma
PMID
PMID39989038
PMC
PMC11848031
Study Number(s)
S1404

Design and Analysis Considerations for Investigating Patient Subgroups of Interest Within Cancer Clinical Trials

Authors
G Mazza;E Culacova;D Enserro;J Dignam;J Unger
Journal / Conference
Journal of the National Cancer Institute Monographs Mar 1;2025(68):22-29
Year
2025
Research Committee(s)
Cancer Care Delivery
PMID
PMID39989043
PMC
PMC11848030

Guideline-Concordant Treatment among Adolescents and Young Adults (AYAs) with Acute Lymphoblastic Leukemia (ALL)

Authors
J Wolfson;A Grimes;M Nuno;S Ramakrishnan;D Dickens;M Roth;W Woods;K Barnett;T Alabi;M Beauchemin;J Levine;M Scialla;K Boayue;C Kerber;O Ponce;S Vargas;G Chang;W Stock;D Hershman;E Curran;A Advani;K O'Dwyer;S Luger;J Liu;D Freyer;L Sung;S Parsons
Journal / Conference
JNCI Cancer Spectrum
Year
2025
Research Committee(s)
Cancer Care Delivery and Leukemia
PMID
PMID40238217
PMC
PMC12121638

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Pancreatic Neuroendocrine Neoplasm (PNEN) Cohort

Authors
S Patel;J Fisher;Y Chae;L Soto;A Kasi;B Konda;M Walshauser;E Parra;J Zhang;C Duault;E Gonzalez-Kozlova;G Manyam;T Holmes;J Zhang;H Chen;D Duose;C Laberiano Fernandez;R Luthra;G Al-Atrash;S Kim-Schulze;H Maecker;I Wistuba;S Gnjatic;J Lee;J Zhang;C Magner;H Chen;E Sharon;M Othus;C Ryan;C Blanke;C Haymaker;R Kurzrock
Journal / Conference
Journal for ImmunoTherapy of Cancer
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID40588371
PMC
PMC12211841
Study Number(s)
S1609

Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced stage classic Hodgkin lymphoma

Authors
S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;S Parsons;J Unger;A Perry;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;S Castellino;B Kahl;J Leonard;S Smith;J Friedberg;A Evens
Journal / Conference
Journal of Clinical Oncology
Year
2025
Research Committee(s)
Lymphoma
PMID
PMID40523203
Study Number(s)
S1826

S2303: Phase II/III Trial of Nivolumab + Paclitaxel + Ramucirumab in Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Authors
A Saeed;S Colby;P Oberstein;D Duda;R Park;R Agarwal;C Figueroa Moseley;R Vaidya;J Unger;K Guthrie;F Rocha;M Senthil;R Safyan;Z Wainberg;S Iqbal;EG Chiorean;P Philip
Journal / Conference
Future Oncology
Year
2025
Research Committee(s)
Gastrointestinal
PMID
PMID40155326
PMC
PMC12051544

SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Authors
N Ghosh;S Bellasea;H Li;A Olszewski;L Bryan;A Danilov;S Smith;M LeBlanc;JW Friedberg
Journal / Conference
JCO Oncology Advances
Year
2025
Research Committee(s)
Lymphoma
PMID
PMID40264918
PMC
PMC12011429
Study Number(s)
S2308

Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801)

Authors
M Othus;E Sharon;M Wu;V Sondak;A Ribas;S Patel
Journal / Conference
Clinical Trials
Year
2025
Research Committee(s)
Melanoma
PMID
PMID40099861
Study Number(s)
S1801